Abstract:Abstract: The tumor suppressor protein p53, a transcription factor playing a key role in cancer prevention, interacts with DNA as its primary means of determining cell fate in the event of DNA damage. When it becomes mutated, it opens damaged cells to the possibility of reproducing unchecked, which can lead to formation of cancerous tumors. Despite its critical role, therapies at the molecular level to restore p53 native function remain elusive, due to its complex nature. Nevertheless, considerable information has been amassed, and new means of investigating the problem have become available. Objectives: We consider structural, biophysical, and bioinformatic insights and their implications for the role of direct and indirect readout and how they contribute to binding site recognition, particularly those of low consensus. We then pivot to consider advances in computational approaches to drug discovery. Materials and methods: We have conducted a review of recent literature pertinent to the p53 protein. Results: Considerable literature corroborates the idea that p53 is a complex allosteric protein that discriminates its binding sites not only via consensus sequence through direct H-bond contacts, but also a complex combination of factors involving the flexibility of the binding site. New computational methods have emerged capable of capturing such information, which can then be utilized as input to machine learning algorithms towards the goal of more intelligent and efficient de novo allosteric drug design. Conclusions: Recent improvements in machine learning coupled with graph theory and sector analysis hold promise for advances to more intelligently design allosteric effectors that may be able to restore native p53-DNA binding activity to mutant proteins. Clinical relevance: The ideas brought to light by this review constitute a significant advance that can be applied to ongoing biophysical studies of drugs for p53, paving the way for the continued development of new methodologies for allosteric drugs. Our discoveries hold promise to provide molecular therapeutics which restore p53 native activity, thereby offering new insights for cancer therapies. Graphical abstract: Structural representation of the p53 DBD (PDBID 1TUP). DNA consensus sequence is shown in gray, and the protein is shown in blue. Red beads indicate hotspot residue mutations, green beads represent DNA interacting residues, and yellow beads represent both.

Understanding the complexity of p53 in a new era of tumor suppression

Targeting p53 pathways: mechanisms, structures, and advances in therapy

p53 tumor suppressor and iron homeostasis.

p53 signaling and autophagy in cancer: a revolutionary strategy could be developed for cancer treatment.

Functional Diversity of P53 in Human and Wild Animals

Blinded by the Light: The Growing Complexity of p53

Progress and Prospects: Roles of P53 in Tumor Development

Emerging Roles of the Tumor Suppressor p53 in Metabolism

Elucidating the chain of command: our current understanding of critical target genes for p53-mediated tumor suppression

Multiple roles of p53 in cancer development: Regulation of tumor microenvironment, m6A modification and diverse cell death mechanisms

P53 and Regulation of Tumor Metabolism

Small Molecule Agents Targeting the P53-Mdm2 Pathway for Cancer Therapy

Cell fate regulation governed by p53: Friends or reversible foes in cancer therapy

Navigating the complexity of p53-DNA binding: implications for cancer therapy

p53-Mediated Indirect Regulation on Cellular Metabolism: From the Mechanism of Pathogenesis to the Development of Cancer Therapeutics

p53 regulates lipid metabolism in cancer

p53's Multifaceted Role in the DNA Damage Response and Tumor Treatment Strategies

A Different Facet of p53 Function: Regulation of Immunity and Inflammation During Tumor Development

p53 in ferroptosis regulation: the new weapon for the old guardian

Gene regulation by the tumor suppressor p53 - The omics era

p53: A tale of complexity and context